



Kubota Vision Announces Kubota Glass Commercialization in the U.S.

Seattle (June 19, 2022) — Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that Kubota Glass is now available through eye care professionals in the U.S.

The Company has selected a prestigious eye care practice to prescribe Kubota Glass for the initial commercialization. Manhattan Vision Associates (“MVA”) in New York will be the first eye care practitioners to be able to prescribe Kubota Glass for their patients. The Company will continue to expand sales channels by increasing the number of eye care professionals who are able to provide the product to their patients.

The Company registered Kubota Glass as a medical device with the Taiwan Ministry of Health and Welfare in May 2021 and the FDA (U.S. Food and Drug Administration) in June 2022.

An eminent and well-known vision care institute in New York, MVA has conducted many successful clinical trials for contact lenses and eyeglasses. Drs. Steven Ali and Arkady Selenow, owners of MVA, have been working on the clinical development of Kubota Glass for almost three years. “It is rewarding to see the culmination of our work now become commercially available. People from around the country have already begun to reach out to us based on our research studies, and we are excited to be the first practice in the U.S. to be able to offer the device to our patients,” stated Dr. Ali.

Dr. Brett O’Connor, a prominent optometrist practicing in Jacksonville, Florida and author of the monthly column *Mastering Myopia*, commented, “Because of the technical design and capabilities of Kubota Glass, it is also currently undergoing clinical trials for evaluation of ocular conditions such as myopia. I am excited to be consulting with Kubota Vision on these trials, and to report the results as they become available.”

Ryo Kubota, MD, PhD, Chairman, President, and CEO of Kubota Vision Inc., stated, “It is a thrill to share this exciting news that we are now accepting orders for Kubota Glass. We will continue conducting clinical trials to accumulate scientific evidence to improve Kubota Glass technology and expand the distribution channels.”

The Company is carefully examining the impact on the consolidated earnings forecast for the fiscal year ending December 31, 2022 (January 1, 2022 to December 31, 2022) and expects the impact to be very small. The impact will be incorporated into the consolidated earnings forecast for the fiscal year ending December 31, 2023 (January 1, 2023 to December 31, 2023) scheduling to be announced in February 2023.

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group’s development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease.

The Company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and a wearable device for myopia control. <https://www.kubotavision.com/>; <https://www.kubotaholdings.co.jp/en/>

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (<https://www.kubotaholdings.co.jp/en/ir/>) and on the SEC's website (<http://www.sec.gov>).

“Kubota Vision”, the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Media and Investor Relations Contact:

Press and Media Inquiries
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp